{"id":"aav-rpe65","safety":{"commonSideEffects":[{"rate":"null","effect":"Vision impairment"},{"rate":"null","effect":"Intraocular pressure increase"}]},"_chembl":{"chemblId":"CHEMBL5396470","moleculeType":null,"molecularWeight":"393.40"},"_fixedAt":"2026-03-30T16:40:09.679346","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AAV RPE65 is a gene therapy that uses an adeno-associated virus (AAV) to deliver a healthy copy of the RPE65 gene to the retina, replacing the faulty gene responsible for inherited retinal dystrophy.","oneSentence":"Gene therapy for RPE65-mediated inherited retinal dystrophy","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:51:05.691Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Leber congenital amaurosis"},{"name":"Inherited retinal dystrophy"}]},"_fixedFields":["pubmed(9)"],"trialDetails":[{"nctId":"NCT00999609","phase":"PHASE3","title":"Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spark Therapeutics, Inc.","startDate":"2012-10","conditions":"Inherited Retinal Dystrophy Due to RPE65 Mutations, Leber Congenital Amaurosis","enrollment":31},{"nctId":"NCT02946879","phase":"","title":"Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)","status":"COMPLETED","sponsor":"MeiraGTx UK II Ltd","startDate":"2016-11","conditions":"Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary","enrollment":15},{"nctId":"NCT02781480","phase":"PHASE1, PHASE2","title":"Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)","status":"COMPLETED","sponsor":"MeiraGTx UK II Ltd","startDate":"2016-04","conditions":"Leber Congenital Amaurosis","enrollment":15},{"nctId":"NCT00516477","phase":"PHASE1","title":"Safety Study in Subjects With Leber Congenital Amaurosis","status":"COMPLETED","sponsor":"Spark Therapeutics, Inc.","startDate":"2007-09","conditions":"Leber Congenital Amaurosis","enrollment":12},{"nctId":"NCT00749957","phase":"PHASE1, PHASE2","title":"Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis","status":"COMPLETED","sponsor":"Beacon Therapeutics","startDate":"2009-06-17","conditions":"Leber Congenital Amaurosis","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"recentPublications":[{"date":"2025","pmid":"40978076","title":"Clinical Research for Inherited Retinal Disease Related Pediatric Blindness: A Preliminary Descriptive Analysis Based on ClinicalTrials.gov.","journal":"Journal of multidisciplinary healthcare"},{"date":"2023 Jul","pmid":"37014074","title":"Gene Supplementation in Mice Heterozygous for the D477G RPE65 Variant Implicated in Autosomal Dominant Retinitis Pigmentosa.","journal":"Human gene therapy"},{"date":"2020 Aug","pmid":"32152517","title":"Improved ocular gene transfer with a Neddylation-site modified AAV-RPE65 vector in rd12 mice.","journal":"Eye (London, England)"},{"date":"2009 Oct","pmid":"19458334","title":"Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA.","journal":"Investigative ophthalmology & visual science"},{"date":"2006 Aug","pmid":"16942444","title":"Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.","journal":"Human gene therapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AAV RPE65","genericName":"AAV RPE65","companyName":"MeiraGTx UK II Ltd","companyId":"meiragtx-uk-ii-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Gene therapy for RPE65-mediated inherited retinal dystrophy Used for Leber congenital amaurosis, Inherited retinal dystrophy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}